凯德尼医疗完成A轮融资,推动肾病管理数字化升级
2019年,北京凯德尼医疗科技有限公司正式宣布完成数千万元人民币A轮融资。本轮融资由顺为资本、凯风创投等知名投资机构参与。这标志着凯德尼医疗在慢性肾病数字化管理领域获得了资本市场的高度认可,也为公司的快速发展注入了强劲动力。
持续获得资本青睐
自2015年成立以来,凯德尼医疗一直专注于通过数字技术改善慢性肾病患者的医疗服务体验。公司在2015年完成天使轮融资,2017年完成pre-A轮融资,此次A轮融资的成功完成,充分体现了投资人对凯德尼医疗商业模式和发展前景的信心。
顺为资本合伙人表示:"慢性肾病是一个巨大的医疗需求市场,而凯德尼医疗通过'肾上线'平台,为患者提供了专业、便捷、高质量的数字健康服务。我们看好凯德尼团队在肾病管理领域的专业能力和创新实践,期待与公司共同推动中国肾病数字医疗的发展。"
肾上线平台快速增长
凯德尼医疗旗下的"肾上线"数字健康平台自推出以来,已经成为国内领先的肾病管理平台之一。平台通过公众号、小程序和"掌上肾医"APP等多种渠道,为肾病患者提供疾病知识科普、用药指导、饮食管理、医生咨询等全方位服务。
截至2019年,"肾上线"平台已经吸引了数十万肾病患者用户,覆盖全国各个省市。平台不仅为患者提供免费的健康教育内容,还推出了个性化的付费管理服务。值得注意的是,付费用户的续费率超过50%,用户满意度高达99%,充分说明了平台服务的专业性和实用性。
AI驱动的创新服务
凯德尼医疗始终坚持技术创新,将人工智能技术深度融入肾病管理服务中。平台利用AI算法为患者提供智能化的健康评估、风险预测和个性化管理方案。通过大数据分析,平台能够帮助医生更准确地了解患者的病情变化,及时调整治疗方案。
此外,平台还开发了智能腹透管理系统,为腹膜透析患者提供远程监测、智能提醒、数据分析等功能,极大地提升了患者的自我管理能力和生活质量。
融资助力业务拓展
凯德尼医疗创始人兼CEO陈绪勇博士表示:"非常感谢投资人对凯德尼医疗的信任和支持。本轮融资将主要用于三个方面:一是继续扩大用户规模,让更多肾病患者受益于我们的数字健康服务;二是加大研发投入,进一步完善AI驱动的智能管理系统;三是加强医疗团队建设,为患者提供更加专业、优质的服务。"
"我们的目标是成为中国乃至全球领先的肾病管理平台,通过数字技术赋能患者和医生,改善慢性肾病的治疗效果,降低医疗成本,最终帮助患者过上更好的生活。"陈绪勇博士补充道。
展望未来
随着A轮融资的完成,凯德尼医疗将进一步加快业务发展步伐。
慢性肾病是全球重大的公共卫生问题,中国有超过1.2亿慢性肾病患者。凯德尼医疗将继续秉承"以患者为中心"的理念,通过数字技术创新,为更多患者带来福音,为推动中国肾病医疗事业的发展贡献力量。
KidneyTec Healthcare Completes Series A Financing, Advancing Digital Transformation of Kidney Disease Management
In 2019, Beijing KidneyTec Medical Technology Co., Ltd. officially announced the completion of a Series A financing round worth tens of millions of yuan. This round was participated by prominent investment institutions including Shunwei Capital and Co-Win Venture Capital. This marks significant recognition from the capital market for KidneyTec Healthcare in the field of chronic kidney disease digital management and injects strong momentum for the company's rapid development.
Continued Capital Market Recognition
Since its establishment in 2015, KidneyTec Healthcare has been dedicated to improving medical service experiences for chronic kidney disease patients through digital technology. The company completed angel round financing in 2015 and pre-A round financing in 2017. The successful completion of this Series A round fully demonstrates investors' confidence in KidneyTec Healthcare's business model and development prospects.
A partner from Shunwei Capital stated: "Chronic kidney disease represents a massive healthcare market need, and KidneyTec Healthcare, through its 'Kidney Online' platform, provides professional, convenient, and high-quality digital health services to patients. We are optimistic about the KidneyTec team's professional capabilities and innovative practices in kidney disease management, and look forward to jointly promoting the development of China's kidney disease digital healthcare."
Rapid Growth of Kidney Online Platform
KidneyTec Healthcare's "Kidney Online" digital health platform has become one of China's leading kidney disease management platforms since its launch. Through multiple channels including WeChat official account, mini-programs, and the "Pocket Kidney Doctor" APP, the platform provides comprehensive services to kidney disease patients, including disease knowledge education, medication guidance, dietary management, and doctor consultations.
By 2019, the "Kidney Online" platform had attracted hundreds of thousands of kidney disease patient users, covering provinces and cities across the country. The platform not only provides free health education content to patients but also offers personalized paid management services. Notably, the renewal rate for paid users exceeds 50%, with user satisfaction reaching 99%, fully demonstrating the professionalism and practicality of the platform's services.
AI-Driven Innovative Services
KidneyTec Healthcare consistently adheres to technological innovation, deeply integrating artificial intelligence technology into kidney disease management services. The platform utilizes AI algorithms to provide patients with intelligent health assessments, risk predictions, and personalized management plans. Through big data analysis, the platform helps doctors more accurately understand patients' condition changes and adjust treatment plans in a timely manner.
Additionally, the platform has developed an intelligent peritoneal dialysis management system that provides remote monitoring, smart reminders, and data analysis functions for peritoneal dialysis patients, greatly enhancing patients' self-management capabilities and quality of life.
Financing to Drive Business Expansion
Dr. Chen Xuyong, founder and CEO of KidneyTec Healthcare, stated: "We are very grateful for the trust and support of our investors. This round of financing will be primarily used in three areas: first, to continue expanding our user base so that more kidney disease patients can benefit from our digital health services; second, to increase R&D investment to further enhance our AI-driven intelligent management system; and third, to strengthen our medical team to provide patients with more professional and high-quality services."
"Our goal is to become the leading kidney disease management platform in China and globally. Through digital technology, we empower patients and doctors, improve treatment outcomes for chronic kidney disease, reduce healthcare costs, and ultimately help patients live better lives," added Dr. Chen Xuyong.
Looking Forward
With the completion of Series A financing, KidneyTec Healthcare will further accelerate its business development.
Chronic kidney disease is a major global public health issue, with over 120 million chronic kidney disease patients in China. KidneyTec Healthcare will continue to uphold a "patient-centered" philosophy, bringing benefits to more patients through digital technology innovation and contributing to the development of China's kidney disease healthcare industry.